Age Does Matter in Adolescents and Young Adults versus Older Adults with Advanced Melanoma: A National Cohort Study Comparing Tumor Characteristics, Treatment Pattern, Toxicity and Response

M.K. van der Kooij, M.J.A.L. Wetzels, M.J.B. Aarts, F.W.P.J. van den Berkmortel, C.U. Blank, M.J. Boers-Sonderen, M.P. Dierselhuis, J.W.B. de Groot, G.A.P. Hospers, D. Piersma, R.S. van Rijn, K.P.M. Suijkerbuijk, A.J. ten Tije, A.A.M. van der Veldt, G. Vreugdenhil, M.W.J.M. Wouters, J.B.A.G. Haanen, A.J.M. van den Eertwegh, E. Bastiaannet, E. Kapiteijn

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Article number2072
Number of pages15
JournalCancers
Volume12
Issue number8
DOIs
Publication statusPublished - 1 Aug 2020

Keywords

  • adolescents
  • advanced melanoma
  • aya
  • braf mutation
  • checkpoint inhibitors
  • choice chemotherapy
  • clinical audit
  • ipilimumab
  • metastatic melanoma
  • microbiome
  • mutations
  • nivolumab
  • open-label
  • outcome research
  • pembrolizumab
  • prospective nation-wide data
  • risk
  • survival
  • targeted therapy
  • young adults
  • SURVIVAL
  • CHOICE CHEMOTHERAPY
  • MICROBIOME
  • AYA
  • BRAF mutation
  • METASTATIC MELANOMA
  • MUTATIONS
  • NIVOLUMAB
  • RISK
  • OPEN-LABEL
  • PEMBROLIZUMAB
  • IPILIMUMAB

Cite this